The AHA today commented on the Food and Drug Administration’s draft guidance for industry and FDA staff on clinical decision support software as part of the agency’s efforts to implement Section 3060(a) of the 21st Century Cures Act. AHA expressed concern that “FDA’s interpretation of certain criteria could result in many existing CDS algorithms being subject to the FDA approval process and ultimately slow the pace of innovation and development of new algorithms to support better patient care and outcomes.” In its letter, AHA shared specific recommendations with FDA and said it “looks forward to working with the FDA to ensure the agency’s regulatory approach to implementing Section 3060(a) is consistent with the language and intent of the Cures Act and prioritizes patient safety while at the same time allowing hospitals and health systems to continue to implement innovative decision support tools.”

Related News Articles

Perspective
AHA released its 2020 Environmental Scan which offers an overview of the trends, statistics and economic forecasts likely to affect patients and providers at…
#HealthCareInnovation Thursday Blog
Maryjane Wurth, AHA executive vice president and chief operating officer, shares strategies and insights gleaned from last week’s J.P. Morgan Healthcare…
#HealthCareInnovation Thursday Blog
A new thought leadership video series highlights key takeaways to create and sustain a culture of transformational performance improvement at health care…
Headline
Department of Health and Human Services Deputy Secretary Eric Hargan will address the AHA’s Rural Health Care Leadership Conference Feb. 3 in Phoenix, the…
Headline
Brian Donley, M.D., CEO of Cleveland Clinic London, will chair AHA's Health Care Systems Council in 2020, and Penny Wheeler, M.D., president and CEO of Allina…
Perspective
Election Day is fewer than 10 months away so get ready, get connected and get involved.